MedPath

Comparison of Proton and Carbon Ion Radiotherapy With Advanced Photon Radiotherapy in Skull Base Meningiomas: The PINOCCHIO Trial.

Not Applicable
Withdrawn
Conditions
Skull Base Meningioma
Interventions
Radiation: Carbon Ion Radiotherapy
Radiation: Hypofractionated Photon Radiotherapy
Radiation: Conventional Photon Radiotherapy
Radiation: Proton Therapy
Registration Number
NCT01795300
Lead Sponsor
University Hospital Heidelberg
Brief Summary

In PINOCCHIO-Triayl, carbon ion radiotherapy is compared to proton and advanced photon radiotherapy in patients with skull base meningiomas. There will be two treatment arms with photons, one arm with hypofractionated photon radiotherapy, and one arm with conventional fractionation. The study is designed as descriptive study on feasibility of the investigated therapies aiming at a comparison of toxicities. The study will serve as a basis for further larger randomized protocols comparing efficacy of the therapies, assuming toxicity is comparable in all four treatment arms. Primary endpoint is toxicity, secondary endpoints are overall survival, progression-free survival and quality of life.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Carbon Ion RadiotherapyCarbon Ion RadiotherapyTreatment Schedule Carbon Ion Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
Hypofractionated Photon TherapyHypofractionated Photon RadiotherapyTreatment Schedule Photon Radiation 3 Gy E Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
Conventional Photon RadiotherapyConventional Photon RadiotherapyTreatment Schedule Photon Radiation 1.8 Gy E Total Dose 57.6 Gy Gy E, 32 fractions, 1.8 Gy E single dose
Proton TherapyProton TherapyTreatment Schedule Proton Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
Primary Outcome Measures
NameTimeMethod
Toxicity graded according to CTCAE Version 4.1 after 1 year1 year

Toxicity graded according to CTCAE Version 4.1 after 1 year

Secondary Outcome Measures
NameTimeMethod
Progression-free survival3 years

Progression-free survival

Overall survival3 years

Overall survival

Quality of Life3 years

Trial Locations

Locations (1)

University Hospital of Heidelberg, Radiation Oncology

🇩🇪

Heidelberg, Germany

© Copyright 2025. All Rights Reserved by MedPath